Blood-based multiplex nanobiosensing of Alzheimer’s disease biomarkers: from nanoengineered ınterfaces to clinical translation
Overall, nanoengineered multiplex biosensors represent a promising route toward accessible blood-based Alzheimer’s disease biomarker profiling, but their implementation in clinical practice will require rigorous analytical validation, scalable manufacturing, and clinically meaningful assay design.